Ginkgo Bioworks Stock

ginkgobioworks.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $785.53MM

Ginkgo Bioworks is the developer of a cell programming platform enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Ginkgo Bioworks before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Ginkgo Bioworks Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Ginkgo Bioworks Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/28/2020 Series E $360MM $xx.xx $4.89B Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Illumina, Reshape Holdings, T. Rowe Price, Viking Global Investors
Price per Share
$xx.xx
Shares Outstanding
2,396,964
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Illumina, Reshape Holdings, T. Rowe Price, Viking Global Investors
12/14/2017 Series D $275MM $xx.xx $1.57B Cascade Investment, General Atlantic, Viking Global Investors, Vital Venture Capital, Y Combinator
Price per Share
$xx.xx
Shares Outstanding
5,763,991
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cascade Investment, General Atlantic, Viking Global Investors, Vital Venture Capital, Y Combinator
06/08/2016 Series C $98.9MM $xx.xx $450MM Allen & Company, Alrai Capital, Baillie Gifford, Cascade Investment, Casdin Capital, Senator Investment Group, Viking Global Investors, Y Combinator
Price per Share
$xx.xx
Shares Outstanding
4,658,503
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Alrai Capital, Baillie Gifford, Cascade Investment, Casdin Capital, Senator Investment Group, Viking Global Investors, Y Combinator
07/08/2015 Series B $51.63MM $xx.xx $200MM Chinarock Capital Management, Data Collective, Felicis Ventures, Id Ventures America, Iglobe Partners, Ken Arnold, Massventures, Os Fund, Vast Ventures, Viking Global Investors, Y Combinator
Price per Share
$xx.xx
Shares Outstanding
4,024,260
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chinarock Capital Management, Data Collective, Felicis Ventures, Id Ventures America, Iglobe Partners, Ken Arnold, Massventures, Os Fund, Vast Ventures, Viking Global Investors, Y Combinator

Ginkgo Bioworks Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Barry Canton
Co-Founder
Peter Boynton
Chief Commercial Officer
Austin Che
Co-Founder
Ena Cratsenburg
Chief Business Officer
Jason Kelly
Co-Founder, Chief Executive Officer & Board Member
Reshma Shetty
Co-Founder, President & Board Member
Tom Knight
Co-Founder

Board

Marjin Dekkers
Christian Henry

Ginkgo Bioworks stock FAQs

plusminus

Can you buy Ginkgo Bioworks stock?

You can no longer buy Ginkgo Bioworks stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Ginkgo Bioworks stock?

You can no longer buy Ginkgo Bioworks stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Ginkgo Bioworks stock?

You can no longer sell stock of Ginkgo Bioworks on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Ginkgo Bioworks stock?

You can no longer sell stock of Ginkgo Bioworks on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Ginkgo Bioworks a public company?

Ginkgo Bioworks is now a public company traded on NYSE with ticker DNA.
plusminus

What is Ginkgo Bioworks’ stock price?

The stock price of Ginkgo Bioworks is $1.18 as of 1/18/24.
plusminus

What is Ginkgo Bioworks’ stock ticker symbol?

The ticker symbol of Ginkgo Bioworks is DNA.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Ginkgo Bioworks News and Media Highlights

Ginkgo Bioworks to Acquire Swiss Bioengineering Firm FGen

FGen, a spinout of ETH Zurich, is a contract research organization specializing in strain development and optimization.

Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm

Project Beacon COVID-19 was started by F-Prime Capital, GV, and the Broad Institute to help implement COVID-19 testing in Massachusetts and its environs.

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Today’s Important Deadline in Securities Class Action Commenced by the Firm – DNA, SRNG

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo...

Eurofins' Clinical Enterprise, Ginkgo Bioworks Partner to Support COVID-19 Testing Program

Operation Expanded Testing Program is designed to provide federally funded COVID-19 testing to children in kindergarten through grade 12, as well as other groups.
Browse Insights
Updated on: Dec 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.